Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Apr 3;9(4):259.
doi: 10.3390/pathogens9040259.

A Systematic Review of Studies Published between 2016 and 2019 on the Effectiveness and Efficacy of Pneumococcal Vaccination on Pneumonia and Invasive Pneumococcal Disease in an Elderly Population

Jacob Dag Berild  1 , Brita Askeland Winje  1 , Didrik Frimann Vestrheim  1 , Hans-Christian Slotved  2 , Palle Valentiner-Branth  3 , Adam Roth  4 , Jann Storsäter  4
Affiliations
Review

A Systematic Review of Studies Published between 2016 and 2019 on the Effectiveness and Efficacy of Pneumococcal Vaccination on Pneumonia and Invasive Pneumococcal Disease in an Elderly Population

Jacob Dag Berild et al. Pathogens. .

Abstract

Adult vaccination is high on the agenda in many countries. Two different vaccines are available for the prevention of pneumococcal disease in adults: a 23-valent polysaccharide vaccine (PPV23), and a 13-valent conjugated vaccine (PCV13). The objective of this review is to update the evidence base for vaccine efficacy and effectiveness of PPV23 and PCV13 against invasive pneumococcal disease and pneumonia among an unselected elderly population. We systematically searched for clinical trials and observational studies published between January 1 2016 and April 17 2019 in Pubmed, Embase, Cinahl, Web of Science, Epistemonikos and Cochrane databases. Risk of bias was assessed using Cochrane Risk of Bias tool for and the Newcastle-Ottawa Scale. Results were stratified by vaccine type and outcome. We identified nine studies on PCV13 and six on PPV23. No new randomized clinical trials were identified. Due to different outcomes, it was not possible to do a meta-analysis. New high-quality observational studies indicate protective vaccine effectiveness for both vaccines against vaccine type pneumonia. Our estimates for the protective vaccine efficacy and effectiveness (VE) of PPV23 on pneumonia and pneumococcal pneumonia overlap with results from previously published reviews. Some of the results indicate that the effectiveness of the PPV23 is best in younger age groups, and that it decreases over time.

Keywords: elderly; invasive pneumococcal disease; pneumococcal vaccines; pneumonia; review.

PubMed Disclaimer

Conflict of interest statement

Hans-Christian Slotved is involved with projects supported by Pfizer.

Figures

Figure 1
Figure 1
Flowchart of literature search. n: number.
Figure 2
Figure 2
Forest plot of PCV 13 vaccine effectiveness estimates without summary estimate. Pn: pneumococcal. VT: Vaccine-type.
Figure 3
Figure 3
Forest plot of PPV23 vaccine effectiveness estimates without summary estimate. Pn: pneumococcal. VT: Vaccine-type. IPD: invasive pneumococcal disease.
See this image and copyright information in PMC

References

    1. Wroe P.C., Finkelstein J.A., Ray G.T., Linder J.A., Johnson K.M., Rifas-Shiman S., Moore M.R., Huang S.S. Aging population and future burden of pneumococcal pneumonia in the United States. J. Infect. Dis. 2012;205:1589–1592. doi: 10.1093/infdis/jis240. - DOI - PubMed
    1. Bonten M.J., Huijts S.M., Bolkenbaas M., Webber C., Patterson S., Gault S., van Werkhoven C.H., van Deursen A.M., Sanders E.A., Verheij T.J., et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N. Engl. J. Med. 2015;372:1114–1125. doi: 10.1056/NEJMoa1408544. - DOI - PubMed
    1. Diao W.Q., Shen N., Yu P.X., Liu B.B., He B. Efficacy of 23-valent pneumococcal polysaccharide vaccine in preventing community-acquired pneumonia among immunocompetent adults: A systematic review and meta-analysis of randomized trials. Vaccine. 2016;34:1496–1503. doi: 10.1016/j.vaccine.2016.02.023. - DOI - PubMed
    1. Falkenhorst G., Remschmidt C., Harder T., Hummers-Pradier E., Wichmann O., Bogdan C. Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) against Pneumococcal Disease in the Elderly: Systematic Review and Meta-Analysis. PLoS ONE. 2017;12:e0169368. doi: 10.1371/journal.pone.0169368. - DOI - PMC - PubMed
    1. Kraicer-Melamed H., O’Donnell S., Quach C. The effectiveness of pneumococcal polysaccharide vaccine 23 (PPV23) in the general population of 50 years of age and older: A systematic review and meta-analysis. Vaccine. 2016;34:1540–1550. doi: 10.1016/j.vaccine.2016.02.024. Corrigendum in 2016, 34, 4083–4084, doi:10.1016/j.vaccine.2016.06.045. - DOI - PubMed

LinkOut - more resources